ATech Sucampo Pharmaceuticals, Inc. recently announced that of Peter Lichntlen, M.D., Ph.D., has come aboard the company. Dr. Lichtlen has joined Sucampo’s wholly owned subsidiary Sucampo AG as Senior Medical Officer and Vice President of European Operations. At Sucampo Dr. Lichtlen will provide leadership and guidance to clinical development activities in the U.S. and Europe. He also will be responsible for overseeing the Medical Affairs teams and advising the global Pharmacovigilance teams.
Dr. Lichtlen previously led B AG of Schlieren, Switzerland from 2004-2010. He earned his M.D. and Ph. D. in molecular biology at the University of Zurich, Switzerland.
“We welcome Dr. Lichtlen to Sucampo and believe he will help to maximize the value of unoprostone isopropyl. We acquired its U.S. and Canadian development and commercialization rights in 2009 and recently acquired additional rights throughout Europe and the rest of the world except for Japan, Taiwan, Korea and the People’s Republic of China,” said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman and Chief Executive Officer.
